MENU
+Compare
JANX
Stock ticker: NASDAQ
AS OF
Sep 4, 12:57 PM (EDT)
Price
$23.05
Change
+$0.01 (+0.04%)
Capitalization
1.38B

JANX Janux Therapeutics Forecast, Technical & Fundamental Analysis

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JANX with price predictions
Sep 03, 2025

JANX's Stochastic Oscillator sits in oversold zone for 5 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JANX advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on JANX as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JANX turned negative on August 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

JANX moved below its 50-day moving average on August 21, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for JANX crossed bearishly below the 50-day moving average on August 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for JANX entered a downward trend on August 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.398) is normal, around the industry mean (19.946). P/E Ratio (0.000) is within average values for comparable stocks, (51.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.076). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. JANX's P/S Ratio (3333.333) is very high in comparison to the industry average of (324.828).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JANX is expected to report earnings to rise 8.69% to -59 cents per share on November 11

Janux Therapeutics JANX Stock Earnings Reports
Q3'25
Est.
$-0.60
Q2'25
Missed
by $0.09
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
The last earnings report on August 07 showed earnings per share of -55 cents, missing the estimate of -46 cents. With 57.20K shares outstanding, the current market capitalization sits at 1.38B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMQHX620.929.56
+1.56%
Rydex Monthly Rbl NASDAQ-100® 2x Strt H
MWEMX49.160.26
+0.53%
MFS Global Equity R6
ICEVX44.670.17
+0.38%
NYLI Epoch International Choice Class A
PCAFX23.470.01
+0.04%
Prospector Capital Appreciation
THISX80.09-0.17
-0.21%
T. Rowe Price Health Sciences I

JANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with SNTI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then SNTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
+0.79%
SNTI - JANX
43%
Loosely correlated
+1.05%
CYCN - JANX
41%
Loosely correlated
-3.39%
TERN - JANX
36%
Loosely correlated
-1.59%
PPBT - JANX
36%
Loosely correlated
N/A
BNTX - JANX
36%
Loosely correlated
-0.20%
More